Logo
Logo

About Fexofenadine Hydrochloride (Form 1) API

Product
  • Therapeutic CategoryRespiratory

  • CAS Number

    138452-21-8

  • API Technology

    Synthetic

  • Dose Form

    Oral Solid/Tablets

  • Dr Reddy's Development Status

    Available

  • Available Regulatory Filing

    USDMF, CEP Submitted, Brazil DMF, EUDMF, Japan DMF, Korea DMF

Mechanism of Action

Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity. Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects. Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats. The clinical significance of these findings is unknown. In laboratory animals, no anticholinergic or alpha1-adrenergic blocking effects were observed. Moreover, no sedative or other central nervous system effects were observed. Radiolabeled tissue distribution studies in rats indicated that fexofenadine does not cross the blood-brain barrier.

Indication

ALLEGRA is an H1-receptor antagonist indicated for:

  • Relief of symptoms associated with seasonal allergic rhinitis in patients ≥ 2 years of age
  • Treatment of uncomplicated skin manifestations of chronic idiopathic urticaria in patients ≥ 6 months of age

Related APIs

Cetirizine Dihydrochloride

Respiratory

arrow

Desloratadine

Respiratory

arrow

Fexofenadine Hydrochloride (Form 1)

Respiratory

arrow

Levocetirizine Dihydrochloride

Respiratory

arrow

Montelukast Sodium

Respiratory

arrow

Request for Quotation

Get in touch with us by filling out the form below. Our team will reach out to you shortly!

Phone
Disclaimer: Products under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act (Bolar Exemption) and not for commercial sale.